Badawy 2009.

Study characteristics
Methods	Study design: single‐centre RCT Study duration: not mentioned
Participants	Inclusion criteria: women diagnosed with unilateral adenocarcinoma of the breast, with positive or negative lymph node status, and with no metastasis who had undergone modified radical mastectomy or breast‐conserving surgery plus full axillary lymph node dissection. All women were menstruating normally and aged 18 to 40 years (basal FSH levels < 10 mU/mL) Country: Egypt Number: GnRH agonist + chemotherapy (n = 40); chemotherapy (n = 40) Age (mean ± SD) GnRH‐agonist + chemotherapy: 30 ± 3.51 years Chemotherapy: 29.2 ± 2.93 years Exclusion criteria: women with macroscopic metastatic spread of the disease
Interventions	Treatment group GnRH‐agonist + chemotherapy Women received subcutaneous goserelin at a dose of 3.6 mg 2 weeks before the initiation of chemotherapy then every 28 days for 6 months Control group Chemotherapy Women received chemotherapy alone. Chemotherapy included FAC, TP, VAC and BEP
Outcomes	Women were followed up monthly for up to 8 months after completion of treatment: Menstruation recovery or maintenance Ovulation: confirmed by serial ultrasound Hormone levels: FSH, LH, estradiol and progesterone
Notes	Funding source: not mentioned Declarations of interest: not mentioned We contacted Badawy 2009 [pers comm] for additional data There was no difference between groups regarding age, body weight, height, number of dissected lymph nodes and serum LH levels. The chemotherapy dose of 2 groups were not significantly different
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not mentioned
Allocation concealment (selection bias)	Low risk	Quote: "sealed, dark envelopes" were used
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not mentioned whether participant/personnel/outcome assessment was blinded or not
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only 1 woman in each group dropped out. Reasons not mentioned
Selective reporting (reporting bias)	Low risk	Results of all outcomes mentioned in Methods section were reported in Results section
Other bias	Unclear risk	Protocol was not mentioned. There was no difference between groups regarding age, body weight, height, number of dissected lymph nodes, serum LH, and chemotherapy dose